Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver
Erlotinib (ERL), a tyrosine kinase inhibitor approved for therapeutic use in non-small cell
lung cancer is further researched for eventual liver cancer treatment. However, conventional …
lung cancer is further researched for eventual liver cancer treatment. However, conventional …
Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer
This study was aimed at developing a nanoparticle strategy to overcome acquired
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …
Role of solid lipid nanoparticles as drug delivery vehicles on the pharmacokinetic variability of Erlotinib HCl
R Rampaka, K Ommi, N Chella - Journal of Drug Delivery Science and …, 2021 - Elsevier
Abstract Background and objectives Erlotinib HCl is approved for the treatment of metastatic
non-small cell lung cancer. Owing to its poor aqueous solubility and presystemic …
non-small cell lung cancer. Owing to its poor aqueous solubility and presystemic …
Erlotinib complexation with randomly methylated β-cyclodextrin improves drug solubility, intestinal permeability, and therapeutic efficacy in non-small cell lung cancer
The purpose of this study was to investigate the impact of anticancer drug erlotinib-randomly
methylated-β-cyclodextrin complex (ERL-RAMEB CD) on drug solubility and dissolution …
methylated-β-cyclodextrin complex (ERL-RAMEB CD) on drug solubility and dissolution …
[HTML][HTML] Comparative of in-vitro evaluation between erlotinib loaded nanostructured lipid carriers and liposomes against A549 lung cancer cell line
FA Gaballu, S Abbaspour-Ravasjani… - Iranian journal of …, 2019 - ncbi.nlm.nih.gov
Erlotinib (ELT) as a small molecule with poor solubility, poor bioavailability, and instability in
gastrointestinal environment, has been considered as a therapeutic agent for Non-Small …
gastrointestinal environment, has been considered as a therapeutic agent for Non-Small …
Co-Delivery of erlotinib and resveratrol via nanostructured lipid Carriers: a synergistically promising approach for cell proliferation prevention and ROS-Mediated …
L Asadollahi, A Mahoutforoush, SS Dorreyatim… - International Journal of …, 2022 - Elsevier
Cancer treatments are always associated with various challenges, and scientists are
constantly trying to find new therapies and methods. Erlotinib (ELT) is a well-known …
constantly trying to find new therapies and methods. Erlotinib (ELT) is a well-known …
The role of Self-Nanoemulsifying drug delivery systems of CDODA-Me in sensitizing Erlotinib-Resistant non–small cell lung cancer
We have investigated the effects of combination treatment involving ERL (erlotinib) with a
glycyrrhetinic acid analog, CDODA-Me in overcoming ERL resistance, providing efforts to …
glycyrrhetinic acid analog, CDODA-Me in overcoming ERL resistance, providing efforts to …
Paclitaxel and erlotinib-co-loaded solid lipid core nanocapsules: assessment of physicochemical characteristics and cytotoxicity in non-small cell lung cancer
Purpose Lung cancer is the leading cause of cancer-related deaths. The aim of this study
was to design solid lipid core nanocapsules (SLCN) comprising a solid lipid core and a …
was to design solid lipid core nanocapsules (SLCN) comprising a solid lipid core and a …
Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer
Non-small cell lung cancer (NSCLC) patients with sensitizing mutations in the exons 18–21
of the epithelial growth factor receptor (EGFR) gene show increased kinase activity of EGFR …
of the epithelial growth factor receptor (EGFR) gene show increased kinase activity of EGFR …
Development, in vitro characterization, antitumor and aerosol performance evaluation of respirable prepared by self-nanoemulsification method
N Naseri, P Zakeri-Milani, H Hamishehkar… - Drug …, 2017 - thieme-connect.com
Poor water solubility and low oral bioavailability limit the clinical application of Erlotinib as
an anticancer. For this purpose, we encapsulated erlotinib in the solid lipid nanoparticles …
an anticancer. For this purpose, we encapsulated erlotinib in the solid lipid nanoparticles …